Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors
E. S. Mozhaitsev, E. V. Suslov, D. A. Rastrepaeva, O. I. Yarovaya, S. S. Borisevich, E. M. Khamitov, D. S. Kolybalov, S. G. Arkhipov, N. I. Bormotov, L. N. Shishkina, O. A. Serova, R. V. Brunilin, A. A. Vernigora, M. B. Nawrozkij, A. P. Agafonov, R. A. Maksyutov, K. P. Volcho, N. F. Salakhutdinov · 2023 · Viruses. 2023;15(1):29. PMID 36680072; PMCID PMC9865139
Published 2022-12-21.
Study data at a glance
- Participants or experimental model
- Cultured-cell antiviral and cytotoxicity comparisons of cage-amide compounds, with computational target modelling; no human participants.
- Reported results
- The paper reports antiviral activity for a family of cage-amides in cell culture. Its lead compound 18a had a reported selectivity index of 18,214 against vaccinia. This is a distinct experimental compound, not a numerical clinical result for Chlodantane. Modelling suggested p37 as a possible target; the paper did not demonstrate direct target binding.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Cell-culture activity does not establish treatment benefit in people. Selectivity index compares cytotoxicity and antiviral concentrations in the assay; it is not a human therapeutic index. The strongest family result must not be transferred to Chlodantane. The paper does not substantiate the Sirius news release’s claim of historical human testing.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Original full-text XML reviewed via Europe PMC, including findings, tables and interpretation; procedural chemistry and virology are not reproduced here
Source access and review scope
Original full-text XML reviewed via Europe PMC, including findings, tables and interpretation; procedural chemistry and virology are not reproduced here
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Journal publication
Open original source or index record ↗
DOI: 10.3390/v15010029
Citation and original source
Original source: E. S. Mozhaitsev, E. V. Suslov, D. A. Rastrepaeva, O. I. Yarovaya, S. S. Borisevich, E. M. Khamitov, D. S. Kolybalov, S. G. Arkhipov, N. I. Bormotov, L. N. Shishkina, O. A. Serova, R. V. Brunilin, A. A. Vernigora, M. B. Nawrozkij, A. P. Agafonov, R. A. Maksyutov, K. P. Volcho, N. F. Salakhutdinov. Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors Viruses. 2023;15(1):29. PMID 36680072; PMCID PMC9865139 2023.
Molekul research summary: https://molekul.io/research/chlodantane-cage-amides-2023. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Chlodantane
N-(adamantan-2-yl)-4-chlorobenzamide, an experimental benzamide from the Russian adamantane program. Its amide linkage distinguishes it from Bromantane’s arylamine.
Bromantane
An adamantane-derived small molecule, also known as Ladasten. The expanded archive connects clinical asthenia studies, operator experiments and preclinical mechanisms, with model-specific limitations and safety findings.